Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased risk of diabetes mellitus five years after an episode of Staphylococcus aureus bacteraemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased abundance of proteobacteria in aggressive Crohn's disease seven years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased risk of diabetes mellitus five years after an episode of Staphylococcus aureus bacteraemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease

    Research output: Contribution to journalReviewResearchpeer-review

  4. Children Attending Day Care Centers are a Year-round Reservoir of Gastrointestinal Viruses

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Patients suffering from Crohn's disease (CD) are at increased risk of infectious diseases, such as pneumococcal infection. The risk increases with immunotherapy. Pneumococcal infection can be prevented by vaccination. Methods: We conducted a randomized trial of the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal conjugated vaccine (PCV13) in groups of CD patients treated with immunosuppressive (IS) drugs in the form of thiopurines (PPV23 n = 28, PCV13 n = 28) alone or in combination with TNF-α antagonists (PPV23 n = 13, PCV13 n = 13) and CD patients not treated with any of these drugs (untreated) (PPV23 n = 30, PCV13 n = 24). In this article, we report the immunogenicity of PPC23 and PCV13 one year after vaccination. Results: No overall differences in vaccine-induced serotype-specific immunoglobulin G (IgG) antibodies or functional antibodies (opsonophagocytic activity (OPA)) were found between the two vaccines. PCV13 induced a higher concentration of IgG antibodies for serotype 9V than PPV23 in untreated patients. In contrast, PPV23 induced higher OPA for serotypes 6B and 19F than PCV13 in IS treated patients. Untreated patients showed generally higher IgG and OPA antibody levels than patients treated with IS and TNF-α antagonists. Conclusions: In conclusion, we found no general differences in the persistence of induced antibodies when comparing PPV23 with PCV13 regardless of treatment and also within treatment groups (IS, IS + TNF-α and untreated). This was demonstrated for both serotype-specific IgG antibodies and as functional antibodies (OPA). Patients treated with thiopurines in combination with TNF-α inhibitors have an impaired immune response against both PPV23 and PCV13, as compared to untreated patients. This study has been registered in the European Clinical Trials Database (EudraCT, record no 2012-002867-86) and ClinicalTrials.gov (record no. NCT01947010).

Original languageEnglish
JournalInfectious diseases (London, England)
Volume51
Issue number9
Pages (from-to)651-658
Number of pages8
ISSN2374-4235
DOIs
Publication statusPublished - Sep 2019

    Research areas

  • 13-valent conjugated pneumococcal vaccine, 23-valent pneumococcal polysaccharide vaccine, Crohn’s disease, inflammatory bowel disease, pneumococcus, vaccination

ID: 57566226